ActoGeniX Raises US 15 Million In Series A Stock Financing
9/19/2006 11:11:09 AM
Ghent, Belgium - ActoGeniX NV, a recently founded biopharmaceutical company, announced the successful closing of its Series A financing round, raising ?11.5 million (~US$15 million) from a syndicate of leading life sciences investors. The transaction was co-led by GIMV (Antwerp, Belgium) and Life Sciences Partners (LSP, Amsterdam, The Netherlands), with Biotech Fund Flanders also participating. ActoGeniX is a spin-off from the Flanders Interuniversity Institute of Biotechnology (VIB) and Ghent University and was founded last June with seed capital from GIMV, VIB and individuals of the management team.
comments powered by